Fulgent Genetics (NASDAQ:FLGT) Releases FY 2026 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of -1.450–1.450 for the period, compared to the consensus earnings per share estimate of -0.590. The company issued revenue guidance of $350.0 million-$350.0 million, compared to the consensus revenue estimate of $343.6 million.

Fulgent Genetics Price Performance

Shares of FLGT opened at $15.33 on Friday. The stock has a market capitalization of $473.85 million, a PE ratio of -7.82 and a beta of 0.86. The business’s fifty day moving average price is $25.66 and its 200 day moving average price is $24.86. Fulgent Genetics has a 12-month low of $14.57 and a 12-month high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last issued its earnings results on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.14. Fulgent Genetics had a negative net margin of 13.62% and a negative return on equity of 2.55%. The company had revenue of $83.34 million for the quarter, compared to analysts’ expectations of $85.38 million. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. As a group, research analysts anticipate that Fulgent Genetics will post -0.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Piper Sandler lifted their target price on Fulgent Genetics from $21.00 to $30.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Fulgent Genetics in a research report on Thursday, January 22nd. Zacks Research downgraded Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 9th. Raymond James Financial reiterated an “outperform” rating and issued a $36.00 target price on shares of Fulgent Genetics in a research note on Friday, November 14th. Finally, Wall Street Zen lowered shares of Fulgent Genetics from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $32.00.

Insider Transactions at Fulgent Genetics

In other Fulgent Genetics news, insider Hanlin Gao sold 1,075 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $28.33, for a total transaction of $30,454.75. Following the transaction, the insider owned 952,890 shares of the company’s stock, valued at approximately $26,995,373.70. This trade represents a 0.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jian Xie sold 1,140 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $28.33, for a total transaction of $32,296.20. Following the sale, the chief operating officer owned 336,749 shares in the company, valued at $9,540,099.17. This trade represents a 0.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 31.76% of the company’s stock.

Fulgent Genetics News Roundup

Here are the key news stories impacting Fulgent Genetics this week:

• Positive Sentiment: Q4 EPS beat consensus, reporting $0.16 vs. estimates near $0.02–$0.03 — a clear near‑term earnings upside that shows some operational strength. Zacks: Q4 Earnings Top Estimates
• Positive Sentiment: Company issued FY‑2026 revenue guidance of $350M, which is roughly above/near consensus (~$343.6M) and signals revenue growth expectations as the business mix shifts. Seeking Alpha: Forecasts $350M 2026 Revenue
• Neutral Sentiment: Management highlighted acquisitions (Bako, StrataDx) that are reshaping the customer mix — these can drive revenue scale over time but bring integration expense and timing uncertainty. Seeking Alpha: Acquisitions Reshape Customer Mix
• Neutral Sentiment: Q4 revenue was $83.34M, a modest miss vs. analyst expectations (~$85M), and the company reported negative net margin and ROE — mixed operating metrics that temper the EPS beat. MarketBeat: Q4 Results & Transcript
• Negative Sentiment: The principal negative: FY‑2026 EPS guidance of about -$1.45 is far below the consensus estimate (~- $0.59), signaling a much larger expected loss than analysts anticipated — the main driver of the sharp selloff. Seeking Alpha: Guidance Details
• Negative Sentiment: Market commentary and coverage note the guidance shock and integration/expense risk as reasons for the heavy share decline; coverage pieces summarize why the stock pulled back sharply after the release. AAII: Why FLGT Stock Is Down

Institutional Trading of Fulgent Genetics

Hedge funds and other institutional investors have recently modified their holdings of the company. Kestra Advisory Services LLC bought a new position in Fulgent Genetics during the fourth quarter valued at about $35,000. Raymond James Financial Inc. acquired a new stake in Fulgent Genetics in the 2nd quarter valued at about $49,000. Quantbot Technologies LP bought a new position in shares of Fulgent Genetics during the 3rd quarter valued at about $61,000. Los Angeles Capital Management LLC acquired a new position in shares of Fulgent Genetics in the 4th quarter worth approximately $218,000. Finally, Advisors Asset Management Inc. raised its holdings in shares of Fulgent Genetics by 2,205.7% in the 4th quarter. Advisors Asset Management Inc. now owns 8,485 shares of the company’s stock worth $223,000 after purchasing an additional 8,117 shares in the last quarter. Institutional investors own 48.06% of the company’s stock.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.